Advanced in AIDS Dysmorphic Syndrome

Meral S. Beksac

Ankara, TR 
Advanced in AIDS Dysmorphic Syndrome
Ankara, TR 
OverviewLocationsClinical Research

Overview

Meral Beksac practices in Ankara, Turkey. Ms. Beksac is rated as an Advanced expert by MediFind in the treatment of AIDS Dysmorphic Syndrome. Her top areas of expertise are Multiple Myeloma, Plasmacytoma, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 245 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of AIDS Dysmorphic Syndrome.

Gender
Female

Locations

Ankara, Turkey
Other Locations
Mamak, 06620, Turkey
Kavaklidere, Turkey
Yenimahalle, Turkey
Dikimevi, 06590, Turkey
Cebeci, 06220, Turkey
Beytepe, 06800, Turkey
Samanpazari, 06100, Turkey
Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 3
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

244 Total Publications

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
Journal: Future oncology (London, England)
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Beksac's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 41 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile